Recombinant activated factor VII in clinical practice: a 2014 update

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 2, 2015, Pages 235-240

  Franchini, Massimo ^a   Crestani, Silvia ^a   Frattini, Francesco ^a   Sissa, Cinzia ^a   Bonfanti, Carlo ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

Acquired FVIII inhibitors; FVII deficiency; Glanzmann s thrombasthenia; Hemophilia; NovoSeven ; Recombinant activated FVII; rFVIIa

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLOOD CLOTTING; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FACTOR VII DEFICIENCY; HEMOPHILIA A; HUMAN; THROMBASTHENIA;

BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; FACTOR VII DEFICIENCY; FACTOR VIIA; HEMOPHILIA A; HEMOSTATICS; HUMANS; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 84939882343     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1114-1     Document Type: Review

References (57)

1. Franchini M, Lippi G (2009) Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost 35:806–813
2. Franchini M, Mannucci PM (2011) Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Pharmacol 72:553–562
3. Franchini M (2013) The modern treatment of hemophilia: a narrative review. Blood Transfus 11:178–182
4. Cromwell C, Aledort LM (2012) FEIBA: a prohemostatic agent. Semin Thromb Hemost 38:265–267
5. Lusher JM (1991) Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 28(3 Suppl 6):3–5
6. Franchini M, Mannucci PM (2013) Hemophilia A in the third millennium. Blood Rev 27:179–184
7. Kisiel W (2009) Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors. J Thromb Haemost 7:1053–1056
8. Hedner U (2008) Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 100:557–562
9. Hedner U, Lee CA (2011) First 20 years with recombinant FVIIa (NovoSeven). Haemophilia 17:e172–e182
10. Hedner U, Glazer S, Pingel K et al (1988) Successful use of rFVIIa in a patient with hemophilia A subjected to synovectomy. Lancet 2:1193
11. Franchini M, Lippi G (2010) Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost 36:485–492
12. Hoffman M (2003) A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17:S1–S5
13. Monroe DM, Hoffman M, Roberts HR (2002) Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22:1381–1389
14. Hoffman M, Dargaud Y (2012) Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 10:1478–1485
15. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM (2007) Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 5:1403–1408
16. Monroe DM, Hoffman M, Oliver JA, Roberts HR (1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:542–547
17. He S, Blombäck M, Jacobsson Ekman G, Hedner U (2003) The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 1:1215–1219
18. Obergfell A, Auvinen MK, Mathew P (2008) Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 14:233–241
19. Key NS, Aledort LM, Beardsley D et al (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80:912–918
20. Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE (2009) Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 15:727–732
21. Santagostino E, Gringeri A, Mannucci PM (1999) Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 104:22–26
22. Lloyd Jones M, Wight J, Paisley S, Knight C (2003) Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 9:464–520
23. Levi M, Peters M, Büller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883–890
24. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, NovoSeven trial (F7HAEM-1510) investigators (2006) Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 95:600–605
25. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4:367–371
26. Young G, Shafer FE, Rojas P, Seremetis S (2008) Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 14:287–294
27. Shapiro AD (2008) Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 6:579–586
28. Giangrande PLF, Wilde JT, Madan B et al (2009) Consensus protocol for the use of recombinant activated factor VII (eptacog alfa (activated); NovoSeven) in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 15:501–508
29. Franchini M, Lippi G (2008) Acquired factor VIII inhibitors. Blood 112:250–255
30. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M (2012) Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 38:433–446
31. Franchini M, Mannucci PM (2013) Acquired haemophilia: a 2013 update. Thromb Haemost 110:1114–1120
32. Huth-Kühne A, Baudo F, Collins P et al (2009) International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 94:566–575
33. Hay CR, Negrier C, Ludlam CA (1997) The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 78:1463–1467
34. Baudo F, de Cataldo F, Gaidano G, Italian registry of acquired hemophilia (2004) Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica 89:759–761
35. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S (2007) Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 13:451–461
36. Baudo F, Collins P, Huth-Kühne A, EACH2 registry contributors et al (2012) Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 120:39–46
37. Mariani G, Bernardi F (2009) Factor VII deficiency. Semin Thromb Hemost 35:400–406
38. Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U (1999) Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 77:131–136
39. Mariani G, Konkle BA, Ingerslev J (2006) Congenital factor VII deficiency: therapy with recombinant activated factor VII—a critical appraisal. Haemophilia 12:19–27
40. Mariani G, Dolce A, Batorova A, on behalf of the STER (Seven Treatment Evaluation Registry) et al (2011) Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation—the surgical STER. Br J Haematol 152:340–346
41. Mariani G, Napolitano M, Dolce A, Seven Treatment Evaluation Registry; International Factor VII Deficiency Study Group et al (2013) Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost 109:238–247
42. Napolitano M, Giansily-Blaizot M, Dolce A et al (2013) Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 98:538–544
43. Frattini F, Bonfanti C, Piccoli P et al (2013) Triple coronary artery bypass graft surgery in a patient with factor VII deficiency: a case report. Haemophilia 19:e268–e269
44. Franchini M, Favaloro EJ, Lippi G (2010) Glanzmann thrombasthenia: an update. Clin Chim Acta 411:1–6
45. Kannan M, Saxena R (2009) Glanzmann’s thrombasthenia: an overview. Clin Appl Thromb Hemost 15:152–165
46. Tengborn L, Petruson B (1996) A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 75:981–982
47. Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y (2006) Glanzmann’s thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 43(1 Suppl 1):S33–S36
48. Chuansumrit A, Sangkapreecha C, Hathirat P (1999) Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 82:1778
49. Poon MC, Demers C, Jobin F, Wu JW (1999) Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 94:3951–3953
50. d’Oiron R, Ménart C, Trzeciak MC et al (2000) Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 83:644–647
51. Poon MC, D’Oiron R, Von Depka M, International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group et al (2004) Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost 2:1096–1103
52. Almeida AM, Khair K, Hann I, Liesner R (2003) The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 121:477–481
53. Giordano P, Lassandro G, Tesse R et al (2013) Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann’s thromboasthenia. Blood Transfus 11:143–147
54. Tagliaferri A, Franchini M (2013) The expanding role of prophylaxis with recombinant activated factor VII. Blood Transfus 11:12–13
55. Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2:899–909
56. Abshire T (2008) Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. Semin Hematol 45(Suppl 1):S3–S6
57. Franchini M, Coppola A, Tagliaferri A, Lippi G (2013) FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 39:772–778